KR102368159B1 - 폴리펩티드, 폴리펩티드 단편, 그의 유도체, 및 그의 적용 - Google Patents

폴리펩티드, 폴리펩티드 단편, 그의 유도체, 및 그의 적용 Download PDF

Info

Publication number
KR102368159B1
KR102368159B1 KR1020197028390A KR20197028390A KR102368159B1 KR 102368159 B1 KR102368159 B1 KR 102368159B1 KR 1020197028390 A KR1020197028390 A KR 1020197028390A KR 20197028390 A KR20197028390 A KR 20197028390A KR 102368159 B1 KR102368159 B1 KR 102368159B1
Authority
KR
South Korea
Prior art keywords
seq
polypeptide
delete delete
group
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197028390A
Other languages
English (en)
Korean (ko)
Other versions
KR20190125373A (ko
Inventor
디 웨이
이 딩
샤오메이 리
웬 위
샤오홍 첸
링 샤오
루이 첸
링 첸
Original Assignee
청두 후타이 바이오메디슨 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201710115604.4A external-priority patent/CN106860855B/zh
Priority claimed from CN201710677602.4A external-priority patent/CN109384830B/zh
Application filed by 청두 후타이 바이오메디슨 컴퍼니 리미티드 filed Critical 청두 후타이 바이오메디슨 컴퍼니 리미티드
Publication of KR20190125373A publication Critical patent/KR20190125373A/ko
Application granted granted Critical
Publication of KR102368159B1 publication Critical patent/KR102368159B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020197028390A 2017-03-01 2018-02-28 폴리펩티드, 폴리펩티드 단편, 그의 유도체, 및 그의 적용 Active KR102368159B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710115604.4A CN106860855B (zh) 2017-03-01 2017-03-01 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN201710115604.4 2017-03-01
CN201710677602.4A CN109384830B (zh) 2017-08-09 2017-08-09 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
CN201710677602.4 2017-08-09
PCT/CN2018/077492 WO2018157807A1 (zh) 2017-03-01 2018-02-28 多肽、多肽片段及其衍生物与应用

Publications (2)

Publication Number Publication Date
KR20190125373A KR20190125373A (ko) 2019-11-06
KR102368159B1 true KR102368159B1 (ko) 2022-03-03

Family

ID=63369746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028390A Active KR102368159B1 (ko) 2017-03-01 2018-02-28 폴리펩티드, 폴리펩티드 단편, 그의 유도체, 및 그의 적용

Country Status (9)

Country Link
US (2) US12011475B2 (https=)
EP (1) EP3590527A4 (https=)
JP (1) JP6965362B2 (https=)
KR (1) KR102368159B1 (https=)
AU (1) AU2018227737B2 (https=)
CA (1) CA3054839C (https=)
IL (1) IL268971B2 (https=)
SG (1) SG11201907914QA (https=)
WO (1) WO2018157807A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965877T3 (es) * 2015-10-27 2024-04-17 Univ Taipei Medical Derivados de indolina para el tratamiento y/o la prevención de enfermedades fibróticas
CN112386678B (zh) * 2019-08-13 2023-07-07 成都惠泰生物医药有限公司 多肽或其衍生物的应用
IL310164A (en) * 2021-08-11 2024-03-01 Hcw Biologics Inc Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036349A1 (en) 1995-05-17 1996-11-21 Manitoba Cancer Treatment And Research Foundation POST-TRANSLATIONAL ACTIVATION OF TGF-β1 INVOLVING THE TSP-1 RECEPTOR CD36
WO2009043525A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of the combination of gluten exorphin c and cd36 as a therapeutic agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
CA2373680C (en) 1999-05-17 2008-07-29 Conjuchem Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1455813B1 (en) 2001-12-18 2015-07-15 mondoBIOTECH AG Interferon gamma in combination with a diagnostic array for use in the improved treatment of idiopathic pulmonary fibrosis
KR20100056508A (ko) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 폐렴 연쇄상 구균 감염의 치료를 위한 ｂｆｇｆ １－２４ 및 임의의 （ａｒｇ ８）바소프레신의 용도
KR20130087585A (ko) * 2010-11-24 2013-08-06 에프. 호프만-라 로슈 아게 저도 염증을 검출하는 방법
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
WO2016054114A1 (en) * 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
CN104313028A (zh) * 2014-09-30 2015-01-28 北京生科东方科技有限公司 抗类风湿关节炎的小肽基因及其生产方法
CN105061600A (zh) * 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 类风湿因子IgA抑制多肽及其应用
CN106860855B (zh) 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036349A1 (en) 1995-05-17 1996-11-21 Manitoba Cancer Treatment And Research Foundation POST-TRANSLATIONAL ACTIVATION OF TGF-β1 INVOLVING THE TSP-1 RECEPTOR CD36
WO2009043525A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of the combination of gluten exorphin c and cd36 as a therapeutic agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Am. J. Respir. Cell Mol. Biol., Vol. 23, No. 2, pp. 204-212(2000.08.01.)
Biochim. Biophys. Acta., Vol. 1852, No. 7, pp. 1323-1333(2015.07.)

Also Published As

Publication number Publication date
US12011475B2 (en) 2024-06-18
CA3054839C (en) 2023-08-29
IL268971B2 (en) 2024-01-01
EP3590527A1 (en) 2020-01-08
AU2018227737A2 (en) 2020-01-30
WO2018157807A1 (zh) 2018-09-07
CA3054839A1 (en) 2018-09-07
EP3590527A4 (en) 2021-01-06
AU2018227737B2 (en) 2021-04-01
US20220072082A1 (en) 2022-03-10
AU2018227737A1 (en) 2019-10-17
US20240390450A1 (en) 2024-11-28
JP2020509061A (ja) 2020-03-26
JP6965362B2 (ja) 2021-11-10
IL268971B1 (en) 2023-09-01
KR20190125373A (ko) 2019-11-06
IL268971A (en) 2019-10-31
SG11201907914QA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
CN106860855B (zh) 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
US20240390450A1 (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
CN109384830B (zh) 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
JP7597398B2 (ja) 組換え神経成長因子のための組成物及び方法
Qi et al. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
US20260115261A1 (en) Collagen peptide-based medicament compositions and uses thereof
CA2371241A1 (en) Tgf-.alpha. polypeptides, functional fragments and methods of use therefor
KR102023058B1 (ko) 이중 이온 pH-민감성 공중합체를 이용한 허혈성 뇌질환 치료용 약물 전달체
KR20150140686A (ko) 신증후군 및 관련 병태의 치료 방법
KR20200138798A (ko) C-말단 cdnf 단편, 이를 포함하는 약학적 조성물 및 그 용도
HK40015944A (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
JP2013253079A (ja) 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
US20230303646A1 (en) Analogs of human fibroblast growth factors
Liu et al. Bioactive nanofiber hydrogel acts on VEGF and VEGF receptor to unleash inhibition effects on corneal neovascularization
CN101503458B (zh) 预防和治疗血管新生的小分子多肽及其应用
CN101730710A (zh) Vegf-d突变体及其用途
US20110092427A1 (en) Polypeptide and pharmaceutical composition containing the polypeptide
US20250263456A1 (en) Use of fgf5 transcript variant-2 and protein thereof in preventing, inhibiting, or treating liver fibrosis
EP4032901A1 (en) Recombinant human neuregulin derivatives and use thereof
JP2000086533A (ja) 新規なアレルギー治療剤
Qi et al. Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal
AU2005201473A1 (en) TGF-alpha polypeptides, functional fragments and methods of use therefor
HK1147502A (en) Polypeptide and pharmaceutical composition containing the polypeptide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5